Jefferies analyst, Anthony Petrone, reiterated his Underperform rating on shares of ResMed (NYSE: RMD) after the DME Survey indicated that ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE